ASCO: combo antibody therapy effective for melanoma
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer
May 17, 2013 |
not rated yet |
0
New protein-targeting drug shows promise in early trial for patients with high-risk CLL
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer
May 17, 2013 |
not rated yet |
0
|
New drug may help immune system fight cancer
(HealthDay)—An experimental drug that taps the power of the body's immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an early study shows.
Cancer
May 16, 2013 |
5 / 5 (3) |
0
|
Adding cetuximab to chemotherapy enables patients with advanced colorectal cancer, liver metastasis to undergo surgery
New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have ...
Cancer
Apr 08, 2013 |
not rated yet |
0
Novel Amgen virus-vaccine shrinks melanoma tumors
Shares of drugmaker Amgen Inc. are rising on news its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test.
Cancer
Mar 20, 2013 |
not rated yet |
0
Study drug is first to help patients with recurrent low-grade ovarian cancer
Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.
Cancer
Feb 08, 2013 |
not rated yet |
0
|
Two-drug combination may slow deadly thyroid cancer
A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs togeth ...
Cancer
Jan 08, 2013 |
5 / 5 (1) |
0
|
Immune system changes may drive aggressiveness of recurrent tumors
Nearly half of the 700,000 cancer patients who undergo surgical removal of a primary tumor each year suffer a recurrence of their disease at some point, and many of those patients will eventually die from their disease. The ...
Cancer
Dec 27, 2012 |
not rated yet |
1
|
Fak inhibitor proves effective against brain tumors in preclinical studies, study shows
(Medical Xpress)—Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. ...
Cancer
Dec 24, 2012 |
not rated yet |
0
New drug dramatically improves survival in Hodgkin lymphoma patients
A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.
Cancer
Jun 27, 2012 |
5 / 5 (1) |
0
|
Novel chemotherapy agent appears to be a promising pancreatic cancer treatment
A novel chemotherapeutic agent, the highly selective MEK1/2 inhibitor BAY 86-9766, may be a promising future treatment for pancreatic ductal adenocarcinoma (PDAC), according to preclinical results presented at the American ...
Cancer
Jun 20, 2012 |
5 / 5 (2) |
0
Dabrafenib shrinks melanoma brain metastases in phase I clinical trial
An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of ...
Cancer
May 17, 2012 |
not rated yet |
0
|
Tivozanib exhibits antitumor activity in renal cancer
(HealthDay) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic ...
Cancer
Apr 10, 2012 |
not rated yet |
0
Ganetespib showed activity in KRAS-mutant NSCLC as monotherapy and in combinations
The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene. The drug was even more active ...
Cancer
Jan 11, 2012 |
not rated yet |
0
MRI predicts survival in locally advanced rectal cancer
A new study has shown that magnetic resonance imaging (MRI) used to evaluate responses to pre-surgery (neo-adjuvant) chemotherapy or radiation may predict survival among patients with advanced rectal cancer. The findings ...
Cancer
Aug 29, 2011 |
5 / 5 (1) |
0
|
